Je was op zoek naar: mutant (Maltees - Engels)

ras mutant (n = 74)
mutant ras (n = 74)

popolazzjoni b’ras mutant
mutant ras population

popolazzjoni bi kras mutant (exon 2)
mutant kras (exon 2) population

popolazzjoni ras mutant cetuximab folfiri flimkien ma’
folfiri cetuximab plus folfiri

0. 0, 4. 3) għal dawk b’ tumuri kras mutant.
0.0, 4.3) for those with mutant kras tumours.

9 pfs – pazjenti bi kras mutant u tat- tip salvaġġ
pfs – patients with mutant and wild type kras wild type kras

0. 77- 1. 48) fil- grupp b’ kras mutant.
0.77-1.48) in the kras mutant group.

deletion mutant ħaj ta’ streptococcus equi strejn tw928 109.0 to 109.4 cfu
live deletion mutant streptococcus equi strain tw928 109.0 to 109.4 cfu

equilis strepe huwa vaċċin li fih is-sustanza attiva live deletion mutant streptococcus equi bacteria.
equilis strepe is a vaccine which contains the active substance live deletion mutant streptococcus equi bacteria.

fil- grupp bi kras mutant ma ’ kien hemm rispons fl- ebda grupp ta ’ kura.
in the kras mutant group there were no responses in either treatment arm.

deletion mutant ħaj ta’ streptococcus equi strejn tw928 109.0 to 109.4 cfu1 1 partijiet li jiffurmaw kolonja
live deletion mutant streptococcus equi strain tw928 109.0 to 109.4 cfu1 1colony forming units

deletion mutant ħaj ta ’ streptococcus equi strejn tw928 109. 0 to 109. 4 cfu1 cfu1: partijiet li jiffurmaw kolonja
live deletion mutant streptococcus equi strain tw928 109.0 to 109.4 cfu1

aktar riżultati mill-prova skont l-istatus tal-mutant ymdd huma miġbura f’tabella 2.
further results from the trial by ymdd mutant status are summarised in table 2.

id- differenza fil- medjan ta ’ pfs fil- grupp b’ kras mutant kien ta ’ 0 ġimgħat.
the difference in median pfs in the kras mutant group was 0 weeks.

ir- rati stabbli tal- marda fil- grupp bi kras mutant kienu 12% għal panitumumab u 8% għal bsc.
the stable disease rates in the kras mutant group were 12% for panitumumab and 8% for bsc.

dan il-prodott fih strejn tal-vaċċin streptococcus equi, li hu oksotrofik deletion mutant ħaj li l- kapaċitajiet li jagħmel il-ħsara ġew imwaqqfa.
this product contains a live auxotrophic deletion mutant streptococcus equi vaccine strain with attenuated virulence.

il- mutant m184v juri tnaqqis ta '< 4 darbiet fis- suxxettibilta' tiegħu għal didanosine u għal zalcitabine; l- importanza klinika ta 'dawn is- sejbiet mhix magħrufa.
the m184v rt mutant shows a < 4-fold decrease in susceptibility to didanosine and zalcitabine; the clinical significance of these findings is unknown.